Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albinterferon alfa-2a
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Albinterferon alfa-2a is a **long-acting recombinant fusion protein drug** consisting of interferon alpha-2a covalently linked to human serum albumin. This design greatly extends its half-life, enabling dosing once every two to four weeks, compared to more frequent administration with conventional interferons or peginterferon. The mechanism of action is typical of type I interferons: albinterferon alfa-2a binds to the interferon alpha/beta receptor (IFNAR1/2) on cells, activating the JAK/STAT pathway, thereby inducing an array of antiviral, antiproliferative, and immunomodulatory genes. It was developed for chronic hepatitis C as an alternative to peginterferon alfa-2a, but global development was discontinued due to safety concerns and business decisions following adverse events in clinical trials[8][2].
- Brand names
- Albuferon
- Other names
- albinterferonalbumin-interferon alpha
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on albinterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albinterferon alfa-2a.